Charging US cancer patients up to five times more for a medication whose invention was 100% paid for by the American people and researched at a public American university...is not “reasonable.” SSWorks
One of those circumstances is if the original patent holder fails to make the benefits of the invention “available to the public on reasonable terms.”
Charging American cancer patients up to five times more for a medication whose invention was 100% paid for by the American people and researched at a public American university—in this case UCLA—is not “reasonable.” We are asking the Biden administration to help us build a system of drug pricing that is based on justice, not greed.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: